Business Context and Reporting Period
This Form 8-K reports on the results of the 2015 Annual Meeting of Stockholders for Histogenics Corporation (noting the metadata reference to Ocugen, Inc. appears to be a discrepancy with the filing text which identifies Histogenics Corporation). The report date is June 24, 2015.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events rather than a financial statement.
Material Changes and Voting Results
Of the 13,220,012 shares entitled to vote, 12,018,872 shares (approximately 90.91%) were represented, constituting a quorum. The following proposals were approved:
- Proposal 1 (Election of Directors): Joshua Baltzell and Kevin Rakin were elected as Class II directors for a term until the 2017 annual meeting. Both received 11,028,603 votes for, with 4,875 votes withheld and 985,394 broker non-votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2015. Votes were 12,015,677 for, 488 against, and 2,707 abstaining.
- Proposal 3 (Executive Compensation): Stockholders approved the advisory non-binding compensation of named executive officers. Votes were 11,018,670 for, 14,308 against, and 500 abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. For further details on the proposals, the filing references the definitive proxy statement on Schedule 14A filed on April 28, 2015.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name (Ocugen, Inc.) and the registrant name in the filing (Histogenics Corporation).
- Review the Schedule 14A Proxy Statement filed on April 28, 2015, for detailed background on the director nominees and executive compensation.
- Confirm the term length for the newly elected directors (Class II, serving until 2017).
- Note the high level of broker non-votes (985,394) on the director election and executive compensation proposals.